Other equities analysts have also recently issued reports about the stock. ValuEngine cut shares of ViewRay from a hold rating to a sell rating in a research report on Friday, September 22nd. Aegis reiterated a buy rating and set a $11.00 price objective on shares of ViewRay in a research report on Saturday, July 22nd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. ViewRay currently has a consensus rating of Buy and an average target price of $10.00.
Shares of ViewRay (NASDAQ VRAY) opened at $8.31 on Friday. The company has a quick ratio of 1.45, a current ratio of 1.73 and a debt-to-equity ratio of -2.62. ViewRay has a twelve month low of $2.67 and a twelve month high of $10.39.
ViewRay (NASDAQ:VRAY) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.02). The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.68 million. The company’s revenue for the quarter was up 133.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.32) earnings per share. research analysts forecast that ViewRay will post -0.81 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its position in shares of ViewRay by 843.2% in the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after acquiring an additional 14,789 shares during the period. Highbridge Capital Management LLC bought a new position in shares of ViewRay in the first quarter valued at approximately $167,000. HighTower Advisors LLC bought a new position in shares of ViewRay in the first quarter valued at approximately $170,000. Wells Fargo & Company MN bought a new position in shares of ViewRay in the first quarter valued at approximately $177,000. Finally, UBS Group AG boosted its position in shares of ViewRay by 447.7% in the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock valued at $192,000 after acquiring an additional 18,375 shares during the period. Institutional investors own 53.64% of the company’s stock.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
What are top analysts saying about ViewRay Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ViewRay Inc. and related companies.